Retrospective Study
Copyright ©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Apr 15, 2019; 11(4): 335-347
Published online Apr 15, 2019. doi: 10.4251/wjgo.v11.i4.335
Significance of HER2 protein expression and HER2 gene amplification in colorectal adenocarcinomas
Xin-Yu Wang, Zhi-Xue Zheng, Yu Sun, Yan-Hua Bai, Yun-Fei Shi, Li-Xin Zhou, Yun-Feng Yao, Ai-Wen Wu, Deng-Feng Cao
Xin-Yu Wang, Yu Sun, Yan-Hua Bai, Yun-Fei Shi, Li-Xin Zhou, Deng-Feng Cao, Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Pathology, Peking University Cancer Hospital and Institute, Beijing 100142, China
Zhi-Xue Zheng, Yun-Feng Yao, Ai-Wen Wu, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Gastrointestinal Cancer Center, Peking University Cancer Hospital and Institute, Beijing 100142, China
Zhi-Xue Zheng, Department of General Surgery, Beijing Jishuitan Hospital, Beijing 100035, China
Deng-Feng Cao, Department of Pathology and Immunology, Washington University School of Medicine, Saint Louis, MO 63110, United States
Author contributions: Wang XY and Zheng ZX contributed equally to this work; all authors helped to perform the research; Wang XY manuscript writing, performing procedures and data analysis; Zheng ZX contribution to writing the manuscript, drafting conception and design; Wang XY and Zheng ZX contribution to writing the manuscript equally; Sun Y manuscript writing, drafting conception and design, performing experiments, and data analysis; Bai YH, Shi YF, Zhou LX, Yao YF and Wu AW contribution to writing the manuscript; Cao DF contribution to writing the manuscript drafting conception and design.
Supported by Special Scientific Research Key Project for Capital Health Development, China, No. 2018-2Z-1026.
Institutional review board statement: This study was reviewed and approved by the Ethics Committee of Beijing Cancer Hospital.
Informed consent statement: Patients were not required to give informed consent to the study because the analysis used anonymous clinical data that were obtained after each patient agreed to treatment by written consent.
Conflict-of-interest statement: All authors declare no conflicts-of-interest related to this article.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Yu Sun, MD, PhD, Associate Professor, Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Pathology, Peking University Cancer Hospital and Institute, 52 Fucheng Road, Haidian District, Beijing 100142, China. sunyu_bch@163.com
Telephone: +86-10-88196700 Fax: +86-10-88196700
Received: December 26, 2018
Peer-review started: December 26, 2018
First decision: January 11, 2019
Revised: February 13, 2019
Accepted: March 16, 2019
Article in press: March 16, 2019
Published online: April 15, 2019
Core Tip

Core tip: The manuscript investigated the prevalence of human epidermal growth factor receptor 2 (HER2) protein overexpression and gene amplification in a large series of surgically resected colorectal adenocarcinomas (CRCs), and evaluated their relationship with clinicopathological parameters and prognosis. We found that HER2 overexpression [immunohistochemical staining (IHC) score 2+ and 3+] is seen in a small percentage of colorectal adenocarcinomas and HER2 gene amplification occurs in the vast majority of tumors with 3+ IHC score but in a much lower percentage of tumors with 2+ IHC score. In addition, although the prevalence of HER2 overexpression by IHC in CRCs is low, HER2 protein status is correlated with clinical outcomes and positive HER2 expression by IHC confers a worse prognosis in 65 years or younger patients with tubular adenocarcinomas.